Your browser doesn't support javascript.
loading
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium.
Afrough, Aimaz; Hashmi, Hamza; Hansen, Doris K; Sidana, Surbhi; Ahn, Chul; Peres, Lauren C; Dima, Danai; Freeman, Ciara L; Puglianini, Omar Castaneda; Kocoglu, Mehmet H; Atrash, Shebli; Voorhees, Peter M; Shune, Leyla; McGuirk, Joseph P; Simmons, Gary; Sborov, Douglas W; Davis, James A; Kaur, Gurbakhash; Sannareddy, Aishwarya; Ferreri, Christopher J; Gaballa, Mahmoud R; Goldsmith, Scott; Nadeem, Omar; Midha, Shonali; Wagner, Charlotte B; Locke, Frederick L; Patel, Krina K; Khouri, Jack; Anderson, Larry D; Lin, Yi.
Afiliação
  • Afrough A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. Aimaz.afrough@utsouthwestern.edu.
  • Hashmi H; Medical University of South Carolina, Charleston, SC, USA.
  • Hansen DK; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Sidana S; Stanford University School of Medicine, Stanford, CA, USA.
  • Ahn C; Peter O'Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, TX, USA.
  • Peres LC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Dima D; Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.
  • Freeman CL; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Puglianini OC; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Kocoglu MH; University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
  • Atrash S; Levine Cancer Institute, Charlotte, NC, USA.
  • Voorhees PM; Levine Cancer Institute, Charlotte, NC, USA.
  • Shune L; The University of Kansas Medical Center, Kansas City, KS, USA.
  • McGuirk JP; The University of Kansas Medical Center, Kansas City, KS, USA.
  • Simmons G; Virginia Commonwealth University Massey Cancer Center, Richmond, VA, USA.
  • Sborov DW; The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
  • Davis JA; Medical University of South Carolina, Charleston, SC, USA.
  • Kaur G; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
  • Sannareddy A; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.
  • Ferreri CJ; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gaballa MR; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Goldsmith S; City of Hope National Medical Center, Duarte, CA, USA.
  • Nadeem O; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Midha S; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Wagner CB; The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA.
  • Locke FL; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
  • Patel KK; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Khouri J; Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA.
  • Anderson LD; Myeloma, Waldenstrom's, and Amyloidosis Program, Hematologic Malignancies and Cellular Therapy Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. larry.anderson@utsouthwestern.edu.
  • Lin Y; Mayo Clinic, Rochester, MN, USA.
Blood Cancer J ; 14(1): 63, 2024 Apr 12.
Article em En | MEDLINE | ID: mdl-38609386
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos Quiméricos / Mieloma Múltiplo Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores de Antígenos Quiméricos / Mieloma Múltiplo Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article